BeOne Medicines Ltd.

BeOne is a global biopharmaceutical organization focused on discovering, developing, and commercializing treatments for cancer patients worldwide. The enterprise concentrates its clinical pipelines and commercial activities primarily on hematology and solid tumor oncology. Its commercialized portfolio includes internally developed therapies such as the Bruton's tyrosine kinase inhibitor BRUKINSA, the anti-PD-1 monoclonal antibody TEVIMBRA, the B-cell lymphoma 2 inhibitor sonrotoclax, and the PARP inhibitor PARTRUVIX, alongside various in-licensed therapies covering diverse hematologic and solid malignancies. Its customer base consists of healthcare systems, hospitals, and cancer patients accessing therapies through public and private healthcare reimbursement frameworks.

The company operates on an international scale, marketing and commercializing products across more than 60 countries and regions, including extensive availability of core treatments in over 75 markets globally. BeOne maintains clinical operations across six continents supported by internal development and manufacturing infrastructure, with primary operational subsidiaries situated in the United States, China, the United Kingdom, and Australia. The enterprise is incorporated and headquartered in Switzerland.

Summary of the business section of BeOne Medicines's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.